Back

Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk: insights from the ETNA-AF-China 1-year follow-up

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulant therapy for atrial fibrillation in clinical practice Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Juan Du

Shanghai (China)

7 More presentations in this session

Presentation thumbnail
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study
Associate Professor I. Diemberger (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Impact of resumption of Oral AntiCoagulation therapy (OAC) after GastroIntestinal Bleeding (GIB) on clinical outcomes in patients with Non-Valvular Atrial Fibrillation (NVAF)
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of NOAC in very elderly atrial fibrillation patients; data from the Korean national health insurance cohort registry
Doctor S. Choi (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry
Professor G. Boriani (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulant therapy for atrial fibrillation in clinical practice

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe
thumbnail
Congress Presentation
Clinical outcomes in >10,000 Asian vs >61,000 Non-Asian race patients with AF randomized to Warfarin vs DOACs: a patient-level meta-analyses from COMBINE AF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources